Skip to main content

Advertisement

SpringerLink
Log in

Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991–2016

  • Original Article
  • Published:
Administration and Policy in Mental Health and Mental Health Services Research Aims and scope Submit manuscript

Abstract

The co-occurrence of schizophrenia and substance use disorder (SUD) is clinically challenging and increasingly prevalent. This study compares trends in hospitalization characteristics of chronic psychotic patients with and without SUD in Israel, before and after introduction of the Community Rehabilitation of Persons with Mental Disability Law in 2000. The National Psychiatric Case Registry provided data on 18,684 adults with schizophrenia/schizoaffective disorders, hospitalized in 1991–2016 (at least once in 2010–2015). Repeated-measures ANOVA was used to measure the effect (and interactions) of group (patients with and without co-occurring disorders (COD)), time-period (Period1: 1991–2000, Period2: 2001–2009, Period3: 2010–2016) and age, on hospitalization measures—average length of stay (LOS), annual number of hospitalizations and hospitalization days. Among non-COD patients hospitalized in all three periods, LOS declined by half from 133.3 days in Period1 to 63.2 in Period3, and the annual number of hospitalizations increased slightly from 0.45 to 0.56. Among COD patients, LOS declined moderately from 82.7 days to 58.3 days, while annual hospitalizations increased dramatically from 0.56 to 0.82. The annual average number of hospitalization days/capita declined from 49.7 in Period1 to 26.3 in Period3 among non-COD patients, yet remained virtually unchanged among COD patients—39.6 and 37.4 in the two periods, respectively. Since introduction of the law, a significant improvement in hospitalization characteristics of chronic psychotic non-COD patients has been noted, whereas the situation worsened somewhat for COD patients. Community rehabilitation services for COD patients in Israel have yet to develop as a suitable alternative to hospitalization, and additional rehabilitation services are urgently needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Adan, A., Arredondo, A. Y., Capella, M. D., Prat, G., Forero, D. A., & Navarro, J. F. (2017). Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: A systematic review. Neuroscience and Biobehavioral Reviews, 75, 361–377. https://doi.org/10.1016/j.neubiorev.2017.01.038.

    Article  PubMed  Google Scholar 

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association.

    Book  Google Scholar 

  • Aviram, U., & Azary-Viesel, S. (2018). Mental health reform in Israel: Challenge and opportunity. Part I: Fundamentals of the reform and the mental health service system on the eve of the reform. Israel Journal of Psychiatry & Related Science, 55(3), 45–54.

    Google Scholar 

  • Aviram, U., Ginath, Y., & Roe, D. (2012). Mental health reforms in Europe: Israel's rehabilitation in the community of persons with mental disabilities law: Challenges and opportunities. Psychiatric Services, 63(2), 110–112. https://doi.org/10.1176/appi.ps.201100009.

    Article  PubMed  Google Scholar 

  • Bahorik, A. L., Newhill, C. E., Queen, C. C., & Eack, S. M. (2014). Under-reporting of drug use among individuals with schizophrenia: Prevalence and predictors. Psychological Medicine, 44(1), 61–69. https://doi.org/10.1017/S0033291713000548.

    Article  CAS  PubMed  Google Scholar 

  • Bar-Hamburger, R. (2006). Psychoactive substance use among Israeli resident from 1990 until 2005. Israel Anti-Drug Authority [Hebrew].

  • Bar-Hamburger, R., Ezrachi, Y., Roziner, I., Nirel, R. (2009). Psychoactive substance use among Israeli resident. Israel Anti-Drug Authority [Hebrew].

  • Bock, P. R., Friedel, W. E., Hanisch, J., Karasmann, M., & Schneider, B. (2004). Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use". Forsch Komplementarmed Klass Naturheilkd, Suppl 1, 23–29. https://doi.org/10.1159/000080572.

    Article  Google Scholar 

  • Bonny-Noach, H. (2019). Harm reduction drug policy in Israel: What has been accomplished and what still needs to be done? Israel Journal of Health Policy Research, 8(1), 75. https://doi.org/10.1186/s13584-019-0343-3.

    Article  PubMed  PubMed Central  Google Scholar 

  • Buckley, P. F. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry, 67(Suppl 7), 5–9.

    Google Scholar 

  • Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research, 35, S93–100.

    Article  Google Scholar 

  • Drake, R. E., Luciano, A. E., Mueser, K. T., Covell, N. H., Essock, S. M., Xie, H., et al. (2016). Longitudinal course of clients with co-occurring schizophrenia-spectrum and substance use disorders in urban mental health centers: A 7-Year prospective study. Schizophrenia Bulletin, 42(1), 202–211. https://doi.org/10.1093/schbul/sbv110.

    Article  PubMed  Google Scholar 

  • D'Souza, D. C., Radhakrishnan, R., Sherif, M., Cortes-Briones, J., Cahill, J., Gupta, S., et al. (2016). Cannabinoids and psychosis. Current Pharmaceutical Design, 22(42), 6380–6391. https://doi.org/10.2174/1381612822666160826105628.

    Article  CAS  PubMed  Google Scholar 

  • Eaton, W. W., Bilker, W., Haro, J. M., Herrman, H., Mortensen, P. B., Freeman, H., et al. (1992). Long-term course of hospitalization for schizophrenia: Part II. Change with passage of time. Schizophrenia Bulletin, 18(2), 229–241. https://doi.org/10.1093/schbul/18.2.229.

    Article  CAS  PubMed  Google Scholar 

  • European Monitoring Centre for Drugs and Drug Addiction. (2013). Co-morbid substance use and mental disorders in Europe: A review of the data, EMCDDA Papers, Publications Office of the European Union, Luxembourg. Retrieved August 9, 2019, from https://www.emcdda.europa.eu/attachements.cfm/att_220660_EN_TDAU13002ENN.pdf.

  • Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157. https://doi.org/10.1016/j.drugalcdep.2011.01.012.

    Article  CAS  PubMed  Google Scholar 

  • Florentin, S., & Raskin, S. (2017). Co-occurring schizophrenia and substance use disorder: Etiological theories and challenges in Israel. Harefuah, 156(11), 715–719.

    PubMed  Google Scholar 

  • Florentin, S., Rosca, P., Raskin, S., Bdolah-Abram, T., & Neumark, Y. (2019). Psychiatric hospitalizations of chronic psychotic disorder patients with and without dual diagnosis, Israel, 1963–2016. Journal of Dual Diagnosis, 15(3), 130–139. https://doi.org/10.1080/15504263.2019.1609149.

    Article  CAS  PubMed  Google Scholar 

  • Gastal, F. L., Andreoli, S. B., Quintana, M. I., Almeida Gameiro, M., Leite, S. O., & McGrath, J. (2000). Predicting the revolving door phenomenon among patients with schizophrenic, affective disorders and non-organic psychoses. Revista de Saude Publica, 34(3), 280–285. https://doi.org/10.1590/s0034-89102000000300011.

    Article  CAS  PubMed  Google Scholar 

  • Green, A. I., Drake, R. E., Brunette, M. F., & Noordsy, D. L. (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry, 164(3), 402–408. https://doi.org/10.1176/ajp.2007.164.3.402.

    Article  Google Scholar 

  • Grinshpoon, A., Abramowitz, M. Z., Lerner, Y., & Zilber, N. (2007). Re-hospitalization of first-in-life admitted schizophrenic patients before and after rehabilitation legislation: A comparison of two national cohorts. Social Psychiatry and Psychiatric Epidemiology, 42(5), 355–359. https://doi.org/10.1007/s00127-007-0167-2.

    Article  PubMed  Google Scholar 

  • Gur, R. E., Petty, R. G., Turetsky, B. I., & Gur, R. C. (1996). Schizophrenia throughout life: Sex differences in severity and profile of symptoms. Schizophrenia Research, 21, 1–12.

    Article  CAS  Google Scholar 

  • Harel-Fisch, Y., & Ezrachi, Y. (2017). Psychoactive drug use among the adult population in Israel—National epidemiological survey 2016. Israel Anti-Drug Authority

  • Hartz, S. M., Pato, C. N., Medeiros, H., Cavazos-Rehg, P., Sobell, J. L., Knowles, J. A., et al. (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry, 71(3), 248–254. https://doi.org/10.1001/jamapsychiatry.2013.3726.

    Article  PubMed  PubMed Central  Google Scholar 

  • Henwood, B. F., Padgett, D. K., & Tiderington, E. (2014). Provider views of harm reduction versus abstinence policies within homeless services for dually diagnosed adults. The Journal of Behavioral Health Services & Research, 41(1), 80–89. https://doi.org/10.1007/s11414-013-9318-2.

    Article  Google Scholar 

  • Hornik-Lurie, T., Zilber, N., & Lerner, Y. (2012). Trends in the use of rehabilitation services in the community by people with mental disabilities in Israel; the factors involved. Israel Journal of Health Policy Research, 1(1), 24. https://doi.org/10.1186/2045-4015-1-24.

    Article  PubMed  PubMed Central  Google Scholar 

  • Janssen, B., Gaebel, W., Haerter, M., Komaharadi, F., Lindel, B., & Weinmann, S. (2006). Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl), 187(2), 229–236. https://doi.org/10.1007/s00213-006-0413-4.

    Article  CAS  Google Scholar 

  • Jiménez-Castro, L., Hare, E., Medina, R., Raventos, H., Nicolini, H., Mendoza, R., et al. (2010). Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry. Schizophrenia Research, 120(1–3), 87–94. https://doi.org/10.1016/j.schres.2010.02.1053.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lichtenberg, P., Kaplan, Z., Grinshpoon, A., Feldman, D., & Nahon, D. (1999). The goals and limitations of Israel’s psychiatric case register. Psychiatric Services, 50, 1043–1048.

    Article  CAS  Google Scholar 

  • Lybrand, J., & Caroff, S. N. (2009). Management of schizophrenia with substance use disorders. Psychiatric Clinics of North America, 32, 821–833. https://doi.org/10.1016/j.psc.2009.09.002.

    Article  Google Scholar 

  • Magura, S. (2008). Effectiveness of dual focus mutual aid for co-occurring substance use and mental health disorders: A review and ynthesis of the “Double Trouble” in recovery evaluation. Substance Use and Misuse, 43, 1904–1926. https://doi.org/10.1080/10826080802297005.

    Article  PubMed  Google Scholar 

  • Mancevski, B., Keilp, J., Kurzon, M., Berman, R. M., Ortakov, V., Harkavy-Friedman, J., et al. (2007). Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology, 40, 83–92. https://doi.org/10.1159/000098488.

    Article  PubMed  Google Scholar 

  • Manuel, J. I., Gandy, M. E., & Rieker, D. (2015). Trends in hospital discharges and dispositions for episodes of co-occurring severe mental illness and substance use disorders. Administration and Policy in Mental Health and Mental Health Services Research, 42(2), 168–175. https://doi.org/10.1007/s10488-014-0540-x.

    Article  PubMed  Google Scholar 

  • Marquez-Arrico, J. E., López-Vera, S., Prat, G., & Adan, A. (2016). Temperament and character dimensions in male patients with substance use disorders: Differences relating to psychiatric comorbidity. Psychiatry Research, 237, 1–8. https://doi.org/10.1016/j.psychres.2016.01.061.

    Article  PubMed  Google Scholar 

  • Ministry of Health. (2015). Information Division, Division of Technologies, Medical Information and Research. Mental Health in Israel. Statistical Abstract (English and Hebrew).

  • Ministry of Justice. (2001). Rehabilitation of the Mentally Disabled in the Community Law of 2001 (RMD) Israeli Law Code (2001), 1746 Jerusalem: Ministry of Justice [Hebrew].

  • Mortensen, P. B., & Eaton, W. W. (1994). Predictors for readmission risk in schizophrenia. Psychological Medicine, 24(1), 223–232.

    Article  CAS  Google Scholar 

  • Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998). Dual diagnosis: A review of etiological theories. Addictive Behaviors, 23, 717–734.

    Article  CAS  Google Scholar 

  • Natan, G. (2010). Treatment of drug dependent persons with co-morbid mental illness. Report to the Israeli Parliament (Knesset), Jerusalem, Israel [Hebrew]. Retrieved August 9, 2019, fromhttps://www.knesset.gov.il/mmm/data/pdf/m02377.pdf

  • Nesvåg, R., Knudsen, G. P., Bakken, I. J., Høye, A., Ystrom, E., Surén, P., et al. (2015). Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: A registry-based study. Social Psychiatry and Psychiatric Epidemiology, 50, 1267–1276. https://doi.org/10.1007/s00127-015-1025-2.

    Article  PubMed  Google Scholar 

  • Radhakrishnan, R., Wilkinson, S. T., & D'Souza, D. C. (2014). Gone to Pot—A review of the association between cannabis and psychosis. Frontiers Psychiatry, 5, 54. https://doi.org/10.3389/fpsyt.2014.00054.

    Article  Google Scholar 

  • Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA Psychiatry, 264, 2511–2518.

    CAS  Google Scholar 

  • Río-Martínez, L., Marquez-Arrico, J. E., Prat, G., & Adan, A. (2020). Temperament and character profile and its clinical correlates in male patients with dual schizophrenia. J. Clin. Med., 9, 1876. https://doi.org/10.3390/jcm9061876.

    Article  CAS  PubMed Central  Google Scholar 

  • Roe, D., Hasson-Ohayon, I., Lachman, M., & Kravetz, S. (2007). Selecting and implementing evidence-based practices in psychiatric rehabilitation services in Israel: A worthy and feasible challenge. Israel Journal of Psychiatry and Related Science, 44(1), 47–53.

    Google Scholar 

  • Roe, D., Lachman, M., & Mueser, K. T. (2010). Editorial: A decade of the Israeli psychiatric rehabilitation law. Israel Journal of Psychiatry and Related Science, 47(3), 164–165.

    Google Scholar 

  • Samaha, A. N. (2014). Can antipsychotic treatment contribute to drug addiction in schizophrenia? Progress in Neuro-psychopharmacology and Biological Psychiatry, 52, 9–16.

    Article  CAS  Google Scholar 

  • Schmidt, L. M., Hesse, M., & Lykke, J. (2011). The impact of substance use disorders on the course of schizophrenia—A 15-year follow-up study: Dual diagnosis over 15 years. Schizophrenia Research, 130(1–3), 228–233. https://doi.org/10.1016/j.schres.2011.04.011.

    Article  PubMed  Google Scholar 

  • Shalit, N., Barzilay, R., Shoval, G., Shlosberg, D., Mor, N., Zweigenhaft, N., et al. (2016). Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: A Comparative sstudy. Journal of Clinical Psychiatry, 77(8), e989–e995. https://doi.org/10.4088/JCP.15m09938.

    Article  Google Scholar 

  • Soyka, M., Albus, M., Kathmann, N., Finelli, A., Hofstetter, S., Holzbach, R., et al. (1993). Prevalence of alcohol and drug abuse in schizophrenic inpatients. European Archives of Psychiatry and Clinical Neuroscience, 242(6), 362–372. https://doi.org/10.1007/BF02190250.

    Article  CAS  PubMed  Google Scholar 

  • Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Canive, J. M., et al. (2006). Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous Mental Disease, 194, 164–172. https://doi.org/10.1097/01.nmd.0000202575.79453.6e.

    Article  PubMed  Google Scholar 

  • Sytema, S., Burgess, P., & Tansella, M. (2002). Does community care decrease length of stay and risk of rehospitalization in new patients with schizophrenia disorders? A comparative case register study in Groningen, The Netherlands; Victoria, Australia; and South-Verona, Italy. Schizophrenia Bulletin, 28(2), 273–281. https://doi.org/10.1093/oxfordjournals.schbul.a006937.

    Article  PubMed  Google Scholar 

  • Talamo, A., Centorrino, F., Tondo, L., Dimitri, A., Hennen, J., & Baldessarini, R. J. (2006). Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophrenia Research, 86, 251–255. https://doi.org/10.1016/j.schres.2006.04.004.

    Article  CAS  PubMed  Google Scholar 

  • Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. (2016). Prevalence of substance use disorders in psychiatric patients: A nationwide Danish population-based study. Social Psychiatry and Psychiatric Epidemiology, 51(1), 129–140. https://doi.org/10.1007/s00127-015-1104-4.

    Article  PubMed  Google Scholar 

  • Winklbaur, B. (2006). Substance abuse in patients with schizophrenia. Dialogues in Clinical Neuroscience, 8(1), 37–43.

    Article  Google Scholar 

Download references

Funding

No external funds were used to support this research.

Author information

Author notes

  1. S. Florentin and Y. Neumark have contributed equally as first authors.

Authors and Affiliations

  1. Hebrew University-Hadassah Braun School of Public Health & Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

    Y. Neumark

  2. Jerusalem Mental Health Center Affiliated with The Hebrew University of Jerusalem, Jerusalem, Israel

    S. Raskin

  3. Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

    T. Bdolah-Abram

  4. Department for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel

    P. Rosca

  5. The Hebrew University of Jerusalem, Jerusalem, Israel

    P. Rosca

  6. Faculty of Medicine, The Hebrew University of Jerusalem, P.O. Box 12272, 9112102, Jerusalem, Israel

    S. Florentin

Authors
  1. S. Florentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Neumark
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Raskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Bdolah-Abram
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Rosca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Florentin.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest. This research was conducted within the framework of SF's thesis.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Florentin, S., Neumark, Y., Raskin, S. et al. Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991–2016. Adm Policy Ment Health 48, 354–362 (2021). https://doi.org/10.1007/s10488-020-01077-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10488-020-01077-4

Keywords

Search

Navigation